Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.
J Infect Dis
; 187(2): 226-42, 2003 Jan 15.
Article
em En
| MEDLINE
| ID: mdl-12552447
ABSTRACT
There is evidence in both simian immunodeficiency virus and human immunodeficiency virus (HIV) type 1 infection that class I major histocompatibility complex-restricted CD8(+) cytotoxic T lymphocytes play a pivotal role in controlling infection and, potentially, in protecting by immunization. Progress has been made in designing strategies to elicit these responses with HIV-1 vaccines, but methods to reproducibly quantify them have posed difficulties. An interferon-gamma enzyme-linked immunospot assay, using peptide pools spanning the HIV-1 genes, was developed and standardized. This method is rapid (2 days), sensitive (threshold of detection, > or =0.005%), quantitative, feasible using cryopreserved cells, and able to define epitope specificities. When this assay was applied to 36 HIV-1-seropositive and 10 HIV-1-seronegative subjects, it proved to be robust (specificity, 100%). When responses in natural infection were compared with vaccine-induced responses, vaccine recipient responses were > or =1 log lower, which confirms the importance of using this sensitive assay as an initial screen in vaccine protocols.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
HIV-1
/
Vacinas contra a AIDS
/
Linfócitos T CD8-Positivos
Limite:
Humans
Idioma:
En
Revista:
J Infect Dis
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Estados Unidos